Preventing end-stage renal disease in diabetic patients - Dual blockade of the renin-angiotensin system (Part II)

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 6, Issue 2, 2005, Pages 55-68

  Jacobsen, Peter Karl ^a,b  

^a STENO DIABETES CENTER   (Denmark)

^b NONE   (Denmark)

Author keywords

ACE 1; Albuminuria; Angiotensin II receptor blockade; Blood pressure; Diabetic nephropathy; Dual blockade; Renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; LYSOZYME; OMAPATRILAT; PLACEBO; RENIN; SPIRONOLACTONE; TRANDOLAPRIL; VALSARTAN; VASOPEPTIDASE INHIBITOR;

ANEMIA; ANGIONEUROTIC EDEMA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEREDITY; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; LONG TERM CARE; MEDICAL LITERATURE; MORBIDITY; MORTALITY; NONHUMAN; PUBLICATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT PLANNING;

EID: 28244489625     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2005.011     Document Type: Review

References (139)

1. Powers AC. Diabetes Mellitus. In: Braunwald E, Fauci AS, Isselbacher KJ et al., editors. Harrison Online. New York: The McGraw-Hill Companies, 2002.
2. Parving H-H, Østerby R, Ritz E. Diabetic nephropathy. In: Brenner BM, editor. The Kidney. Philadelphia: WB Saunders, 2000:1731-73.
3. Parving H-H, Viberti GC, Keen H, Christiansen JS, Lassen NA. Hemodynamic factors in the genesis of diabetic microangiopathy. Metabolism 1983;32(9):943-9.
4. Porte D, Jr., Schwartz MW. Diabetes complications: why is glucose potentially toxic? Science 1996;272: 699-700.
5. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998;352:213-19.
6. Cooper ME. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001;44:1957-72.
7. Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 1982; 307:652-9.
8. Hostetter TH, Rennke HG, Brenner BM. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 1982;72: 375-80.
9. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998;339:1448-56.
10. Fogo AB. Progression and potential regression of glomerulosclerosis. Kidney Int 2001;59:804-19.
11. Rossing P. Promotion, prediction and prevention of progression of nephropathy in Type 1 diabetes mellitus. Diabet Med 1998;15:900-19.
12. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving H-H. Progression of diabetic nephropathy. Kidney Int 2001; 59:702-09.
13. Jacobsen P, Tarnow L, Carstensen B, Hovind P, Poirier O, Parving H-H. Genetic variation in the renin-angiotensin system and progression of diabetic nephropathy. J Am Soc Nephrol 2003;14:2843-50.
14. Bjorck S, Mulec H, Johnsen SA, Norden G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992;304:339-43.
15. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118:129-38.
16. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62.
17. Bilous RW. Baseline and change in proteinuria and the risk of renal functional loss in the Irbesartan Diabetic Nephropathy Trial (IDNT). Diabet Med 2003;20(suppl.2):1-33.
18. Ruggenenti P, Perna A, Remuzzi G. Retarding progression of chronic renal disease: The neglected issue of residual proteinuria. Kidney Int 2003;63:2254-61.
19. De Zeeuw D, Remuzzi G, Parving H-H et al. Proteinuria reduction during antihypertensive therapy predicts renal and cardio-vascular protection in patients with Type 2 diabetic nephropathy. Diabetologia 2003;46(Suppl. 2):A339.
20. De Jong PE, Navis G, De Zeeuw D. Renoprotective therapy: titration against urinary protein excretion. Lancet 1999;354:352-3.
21. Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J (Clin Res Eday)1982;285:685-8.
22. Parving H-H, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983;1 1175-9.
23. Parving H-H, Jacobsen P, Rossing K, Smidt UM, Hommel E, Rossing P. Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy. Kidney Int 1996; 49:1778-82.
24. Rossing P, Hougaard P, Borch-Johnsen K, Parving H-H. Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. BMJ 1996;313:779-84.
25. Mooser V, Nussberger J, Juillerat L et al. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol 1990;15:276-82.
26. van den Meiracker AH, Man in 't Veld AJ, Admiraal PJ et al. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? J Hypertens 1992;10:803-12.
27. Rousseau MF, Konstam MA, Benedict CR et al. Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor. Am J Cardiol 1994; 73:488-93.
28. Roig E, Perez-Villa F, Morales M et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000;21:53-7.
29. Hollenberg NK, Fisher ND, Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 1998;32:387-92.
30. Ritz E. Chymase: a potential culprit in diabetic nephropathy? J Am Soc Nephrol 2003;14:1952-4.
31. Huang XR, Chen WY, Truong LD, Lan HY. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 2003;14: 1738-47.
32. Vanhoutte PM. Endothelium and control of vascular function. State of the Art lecture. Hypertension 1989; 13(6 Pt 2):658-67.
33. Allen TJ, Cao Z, Youssef S, Hulthen UL, Cooper ME. Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies. Diabetes 1997; 46:1612-18.
34. Nabokov A, Amann K, Gassmann P, Schwarz U, Orth SR, Ritz E. The renoprotective effect of angiotensin-converting enzyme inhibitors in experimental chronic renal failure is not dependent on enhanced kinin activity. Nephrol Dial Transplant 1998;13:173-6.
35. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000;52:415-72.
36. Burns KD. Angiotensin II and its receptors in the diabetic kidney. Am J Kidney Dis 2000;36449-67.
37. Wolf G, Ziyadeh FN, Thaiss F et al. Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin Type 2 receptor. J Clin Invest 1997;100:1047-58.
38. Cao Z, Kelly DJ, Cox A et al. Angiotensin Type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis. Kidney Int 2000;58:2437-51.
39. Cao Z, Bonnet F, Candido R et al. Angiotensin Type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury. J Am Soc Nephrol 2002;13:1773-87.
40. Wolf G. "The road not taken": role of angiotensin II Type 2 receptor in pathophysiology. Nephrol Dial Transplant 2002; 17:195-8.
41. Cao Z, Forbes JM, Cooper ME. Pivotal role of the AT2 receptor subtype in mediating angiotensin II induced renal VEGF expression. J Am Soc Nephrol 2002;13:149A.
42. Wolf G. Angiotensin II as a mediator of tubulointerstitial injury. Nephrol Dial Transplant 2000;15(Suppl 6):61-3.
43. Ma L, Fogo AB. Role of angiotensin II in glomerular injury. Semin Nephrol 2001;21:544-53.
44. Komine N, Khang S, Wead LM, Blantz RC, Gabbai FB. Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels. Am J Kidney Dis 2002;39:159-64.
45. Campbell DJ, Kladis A, Valentijn AJ. Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol 1995;26: 233-40.
46. Cao Z, Cooper ME, Wu LL et al. Blockade of the renin-angiotensin and endothelin systems on progressive renal injury. Hypertension 2000;36:561-8.
47. Ots M, Mackenzie HS, Troy JL, Rennke HG, Brenner BM. Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrol 1998;9:224-30.
48. Ma L-J, Nakamura S, Nakamura I, Marcantoni CFAB. High dose angiotensin II type 1 receptor antagonist (AT1RA) and angiotensin converting enzyme inhibitor (ACEI) in Regression of Glomerulasclerosis. J Am Soc Nephrol 2002;13:342A.
49. Cao Z, Bonnet F, Davis B, Allen TJ, Cooper ME. Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats. Clin Sci (Londay)2001;100:591-9.
50. Zoja C, Corna D, Camozzi D et al. How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach. J Am Soc Nephrol 2002;13:2898-908.
51. Menard J, Campbell DJ, Azizi M, Gonzales MF. Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats. Circulation 1997;96:3072-8.
52. Webb RL, Navarrete AE, Davis S, de Gasparo M. Synergistic effects of combined converting enzyme inhibition and angiotensin II antagonism on blood pressure in conscious telemetered spontaneously hypertensive rats. J Hypertens 1998;16:843-52.
53. Bos H, Henning RH, De Boer E et al. Addition of AT1 blocker fails to overcome resistance to ACE inhibition in adriamycin nephrosis. Kidney Int 2002;61:473-80.
54. Remuzzi A, Gagliardini E, Donadoni C et al. Effect of angiotensin II antagonism on the regression of kidney disease in the rat. Kidney Int 2002;62:885-94.
55. Hollenberg NK. Implications of species difference for clinical investigation: studies on the renin-angiotensin system. Hypertension 2000;35(1 Pt 2):150-4.
56. Azizi M, Chatellier G, Guyene TT, Murieta-Geoffroy D, Menard J. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation 1995;92:825-34.
57. Azizi M, Guyene TT, Chatellier G, Wargon M, Menard J. Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension 1997;29:634-40.
58. Mogensen CE, Neldam S, Tikkanen I et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440-4.
59. Jacobsen P, Andersen S, Rossing K, Hansen BV, Parving H-H. Dual blockade of the renin-angiotensin system in Type 1 patients with diabetic nephropathy. Nephrol Dial Transplant 2002;17:1019-24.
60. Rossing K, Christensen PK, Jensen BR, Parving H-H. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 2002;25:95-100.
61. Jacobsen P, Andersen S, Jensen BR, Parving H-H. Additive effect of ACE inhibition and angiotensin II receptor blockade in Type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 2003;14:992-9.
62. Parvanova A, Pisoni R, Dimitrov BD et al. Relative renoprotective effect of ACE inhibitors (ACEi), angiotensin II antagonists (ATA), ACEi and ATA combination and dihydropyridine calcium channel blockers (dCCBs) in overt diabetic nephropathy of Type 2 diabetes. J Am Soc Nephrol 2001;12:153A.
63. Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens 2000;18:89-95.
64. Russo D, Minuteutolo R, Pisani A et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001;38:18-25.
65. Ferrari P, Marti HP, Pfister M, Frey FJ. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. J Hypertens 2002;20: 125-30.
66. Kincaid-Smith P, Fairley K, Packham D. Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria. Nephrol Dial Transplant 2002;17:597-601.
67. Luno J, Barrio V, Goicoechea MA et al. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies. Kidney Int 2002;62(Suppl 82): 47-52.
68. Tylicki L, Rutkowski P, Renke M, Rutkowski B. Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis. Short-term observation. Am J Nephrol 2002;22:356-62.
69. Campbell R, Sangalli F, Perticucci E et al. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 2003;63: 1094-103.
70. Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving H-H. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 2003;63:1874-80.
71. Rossing K, Jacobsen P, Pietraszek L, Parving H-H. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: A randomized double-blind crossover trial. Diabetes Care 2003;26:2268-74.
72. Agarwal R. Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int 2001;59:2282-89.
73. Gibbs CR, Beevers DG, Lip GY. The management of hypertensive disease in black patients. QJM 1999;92: 187-92.
74. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001;344:1351-7.
75. Andersen S, Rossing P, Juhl TR, Deinum J, Parving H-H. Optimal dose of losartan for renoprotection in diabetic nephropathy. Nephrol Dial Transplant 2002;17: 1413-18.
76. Laverman GD, Navis G, Henning RH, De Jong PE, De Zeeuw D. Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 2002;62: 1020-5.
77. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117-24.
78. Lijnen P, Fagard R, Staessen J, Verschueren LJ, Amery A. Dose response in captopril therapy of hypertension. Clin Pharmacol Ther 1980;28:310-15.
79. Gomez HJ, Cirillo VJ, Sromovsky JA et al. Lisinopril dose-response relationship in essential hypertension. Br J Clin Pharmacol 1989;28:415-20.
80. Whalen JJ. Definition of the effective dose of the converting-enzyme inhibitor benazepril. Am Heart J 1989; 117:728-34.
81. Eber B, Brussee H, Rotman B, Kramer R, Klein W. Evaluation of the antihypertensive effect of lisinopril compared with nifedipine in patients with mild to severe essential hypertension. Angiology 1992;43:482-9.
82. Reeves RA, Lin CS, Kassler-Taub K, Pouleur H. Dose-related efficacy of irbesartan for hypertension: an integrated analysis. Hypertension 1998;31:1311-16.
83. Rossing K, Christensen PK, Hansen BV, Carstensen B, Parving H-H. Optimal dose of candesartan for renoprotection in Type 2 diabetic patients with nephropathy: A double-blind randomized cross-over study. Diabetes Care 2003;26: 150-5.
84. Buter H, Navis G, Dullaart RP, De Zeeuw D, De Jong PE. Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM. Nephrol Dial Transplant 2001;16:771-5.
85. Andersen S, Jacobsen P, Tarnow L, Rossing P, Juhl TR, Parving H-H. Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy. Nephrol Dial Transplant 2003;18:293-7.
86. Gansevoort RT, De Zeeuw D, De Jong PE. Dissociation between the course of the hemodynamic and antiproteinuric effects of angiotensin I converting enzyme inhibition. Kidney Int 1993;44:579-84.
87. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000;160:685-93.
88. Apperloo AJ, De Zeeuw D, De Jong PE. A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 1997;51:793-7.
89. Hansen HP, Rossing P, Tarnow L, Nielsen FS, Jensen BR, Parving H-H. Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy. Kidney Int 1995;47:1726-31.
90. Freudenthaler SM, Schreeb K, Korner T, Gleiter CH. Angiotensin II increases erythropoietin production in healthy human volunteers. Eur J Clin Invest 1999;29:816-23.
91. Freudenthaler SM, Schenck T, Lucht I, Gleiter CH. Fenoterol stimulates human erythropoietin production via activation of the renin angiotensin system. Br J Clin Pharmacol 1999;48:631-4.
92. Gossmann J, Burkhardt R, Harder S et al. Angiotensin II infusion increases plasma erythropoietin levels via an angiotensin II Type 1 receptor-dependent pathway. Kidney Int 2001;60:83-6.
93. Shoji T, Suzuki A, Takabataka Y et al. The impact of the combination of losartan and enalapril on erythropoiesis in Japanese patients with chronic glomerulonephritis. J Am Soc Nephrol 2001;12:411A.
94. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving H-H. Renoprotective effects of angiotensin II receptor blockade in Type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000;57:601-06.
95. Buter H, van Tol A, Navis GJ et al. Angiotensin II receptor antagonist treatment lowers plasma total and very low + low density lipoprotein cholesterol in Type 1 diabetic patients with albuminuria without affecting plasma cholesterol esterification and cholesteryl ester transfer. Diabet Med 2000;17: 550-2.
96. Andersen S, Tank JE, Brenner BM. Renal and Systemic Manifestations of Glomerular Disease. In: Brenner BM, editor. The Kidney. Philadelphia: WB Saunders, 2000:1871-1900.
97. Laverman GD, Andersen S, Rossing P, Navis G, De Zeeuw D, Parving H-H. Dose-dependent reduction of proteinuria by losartan does not require reduction of blood pressure. J Am Soc Nephrol 2002;13:265A.
98. Brenner BM, Cooper ME, De Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-9.
99. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N Engl J Med 2001;345:851-60.
100. Parving H-H, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. N Engl J Med 2001;345:870-8.
101. Huang ES, Meigs JB, Singer DE. The effect of interventions to prevent cardiovascular disease in patients with Type 2 diabetes mellitus. Am J Med 2001;111:633-42.
102. Andersen S, Blouch K, Bialek J, Deckert M, Parving H-H, Myers BD. Glomerular permselectivity in early stages of overt diabetic nephropathy. Kidney Int 2000;58(5):2129-37.
103. Deen WM, Satvat B. Determinants of the glomerular filtration of proteins. Am J Physiol 1981;241:F162-F170.
104. Deckert T, Kofoed-Enevoldsen A, Vidal P, Norgaard K, Andreasen HB, Feldt-Rasmussen B. Size- and charge selectivity of glomerular filtration in Type 1 (insulin-dependent) diabetic patients with and without albuminuria. Diabetologia 1993; 36:244-51.
105. Lansang MC, Price DA, Laffel LM et al. Renal vascular responses to captopril and to candesartan in patients with Type 1 diabetes mellitus. Kidney Int 2001;59:1432-8.
106. Muirhead N, Feagan BF, Mahon J et al. The effects of valsartan and captopril on reducing microalbuminuria in patients with Type 2 diabetes mellitus: A Placebo-Controlled Trial. Current Therapeutic Research 1999;60:650-60.
107. Lacourciere Y, Belanger A, Godin C et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive Type 2 diabetics with early nephropathy. Kidney Int 2000;58:762-9.
108. Hilgers KF, Mann JF. ACE inhibitors versus AT(1) receptor antagonists in patients with chronic renal disease. J Am Soc Nephrol 2002;13:1100-08.
109. Price DA, Porter LE, Gordon M et al. The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol 1999;10:2382-91.
110. Jacobsen P, Rossing K, Rossing P et al. Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney Int 1998;53:1002-06.
111. Parving H-H, Jacobsen P, Tarnow L et al. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. BMJ 1996;313:591-4.
112. Andersen S, Tarnow L, Cambien F et al. Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? Kidney Int 2002;62:192-8.
113. Bos H, Andersen S, Rossing P et al. Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. Kidney Int Suppl 2000; 75:S32-S37.
114. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.
115. Stergiou GS, Skeva II, Baibas NM et al. Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension. J Cardiovasc Pharmacol 2000;35:937-41.
116. Weir MR, Weber MA, Neutel JM, Vendetti J, Michelson EL, Wang RY. Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial. ACTION Study Investigators. Am J Hypertens 2001;14(6 Pt 1):567-72.
117. Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, Cohn JN. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group. Circulation 1999;99:2658-64.
118. Hamroff G, Katz SD, Mancini D et al. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 1999;99:990-2.
119. McKelvie RS, Yusuf S, Pericak D et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD)pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999;100:1056-64.
120. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
121. McMurray JJV, Östergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-71.
122. Kobori H, Harrison-Bernard LM, Navar LG. Urinary excretion of angiotensinogen reflects intrarenal angiotensinogen production. Kidney Int 2002;61:579-85.
123. Kobori H, Nishiyama A, Navar LG. Urinary angiotensinogen originates from kidney in angiotensin (Ang) II-induced hypertension. J Am Soc Nephrol 2002;13:147A.
124. Kobori H, Nishiyama A, Harrison-Bernard LM, Navar LG. Urinary angiotensinogen as an indicator of intrarenal Angiotensin status in hypertension. Hypertension 2003; 41:42-49.
125. Thongboonkerd V, Klein JB, Pierce WM, Jevans AW, Arthur JM. Sodium loading changes urinary protein excretion: a proteomic analysis. Am J Physiol Renal Physiol 2003;284(6):F1155-63. Epub 2003 Feb 11.
126. Nakao N, Yoshimura, A, Morita H, Inui K, Ideura T. Effect of timing of administration on the antihypertensive and antiproteinuric activity of angiotensin-converting enzyme inhibitor. J Am Soc Nephrol 2002;13:243A.
127. Haverdings RF, Haas M, Navis G et al. Renal targeting of captopril selectively enhances the intrarenal over the systemic effects of ACE inhibition in rats. Br J Pharmacol 2002;136: 1107-16.
128. Haverdings RF, De Zeeuw D, Moolenaar F. Subcutaneous administration of captopril-lysozyme: improved antiproteinuric response by 24-Hour exclusive renal ACE inhibition. J Am Soc Nephrol 2002;13:266A.
129. Epstein M. Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift. J Hypertens 2001 19:829-42.
130. Ibrahim HN, Hostetter TH. Aldosterone in renal disease. Curr Opin Nephrol Hypertens 2003;12(2):159-64.
131. Bravo EL. Aldosterone and specific aldosterone receptor antagonists in hypertension and cardiovascular disease. Curr Hypertens Rep 2003;5:122-5.
132. Pitt B. "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther 1995;9:145-9.
133. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003;41:64-8.
134. Krum H, Nolly H, Workman D et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002;40:117-23.
135. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 2001;345:925-6.
136. Weber MA. Vasopeptidase inhibitors. Lancet 2001; 358:1525-32.
137. Cao Z, Burrell LM, Tikkanen I, Bonnet F, Cooper ME, Gilbert RE. Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats. Kidney Int 2001;60:715-21.
138. Taal MW, Nenov VD, Wong W et al. Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone. J Am Soc Nephrol 2001; 12:2051-9.
139. Coats AJ. Omapatrilat--the story of Overture and Octave. Int J Cardiol 2002;86:1-4.